The incidence of invasive pneumococcal serotype 3 disease in the Danish population is not reduced by PCV-13 vaccination

Slotved, Hans Christian; Dalby, Tine; Harboe, Zitta Barrella; Valentiner‐Branth, Palle; Casadevante, Victoria Fernández de; Espenhain, Laura; Fuursted, Kurt; Konradsen, Helle Bossen

doi:10.1016/j.heliyon.2016.e00198

Cited by 45 publications

(37 citation statements)

References 12 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The evolution of serotypes causing the majority of pneumococcal pneumonias complicated by PE or empyema shows there was a reduction in serotypes 1 and 19A, the latter not significantly, but not serotype 3. Many studies have shown that serotype 3 continues to produce invasive pneumococcal disease despite being included in the PCV13 . Antachopoulos et al reported a high incidence of complicated pneumonia caused by serotype 3, and a third of these patients had received complete PCV13 vaccination.…”

Section: Discussionmentioning

confidence: 99%

Complicated pneumococcal pneumonia with pleural effusion or empyema in the 13‐valent pneumococcal conjugate vaccine era

Díaz-Conradi

Hernández

García‐García

et al. 2019

Pediatric Pulmonology

View full text Add to dashboard Cite

Aim: The aim was to analyze the epidemiological, microbiological and clinical characteristics of patients with complicated pneumococcal pneumonia with pleural effusion (PE) or empyema. Method: Prospective study in three Catalan hospitals in persons aged <18 years diagnosed with complicated pneumonia with PE or empyema with isolation of Streptococcus pneumoniae in blood or pleural fluid by culture or real-time PCR between January 2012 and June 2016. Patients were divided into <2 years and 2-17 years age groups. Epidemiological, microbiological, and clinical data of patients were compared annually in both groups. PCV13 vaccination coverage increased from 48.2% in 2012 to 74.5% in 2015. Results:We included 143 patients. The incidence of pneumococcal pneumonia was 6.83 cases × 10 −5 persons/year in cases with PE or empyema and 2.09 cases × 10 −5 person-years in cases without (rate ratio [RR]: 3.27; 2.25-4.86; P < 0.001). Empyema was more frequent than PE (79.7% vs 20.3%, P < 0.005). Of 143 cases studied, 93 (65.0%, P < 0.001) were diagnosed by real-time-PCR, 43 (30.1%) by culture and RT-PCR and 7 (4.9%) by culture only. PCV13 serotypes were more frequent in complicated than in uncomplicated pneumonia (116/142, 81.7% vs 27/45, 60.0%; P = 0.003), especially serotype 1 (41/142, 28.9% vs 6/45, 13.3%, P : 0.036). From 2012 to 2015 there was a significant reduction in serotype 1 (16/43, 37.2% vs 3/27, 11.1%, P = 0.026), and a trend to an increase in non-PCV13 serotypes (6/43, 14% vs 9/27, 33.3%, P = 0.054). Conclusions:A directly proportional relationship was observed between the reduction in pneumonia complicated with PE or empyema and a significant

show abstract

Section: Discussionmentioning

confidence: 99%

Complicated pneumococcal pneumonia with pleural effusion or empyema in the 13‐valent pneumococcal conjugate vaccine era

Díaz-Conradi

Hernández

García‐García

et al. 2019

Pediatric Pulmonology

View full text Add to dashboard Cite

show abstract

“…Many studies from different geographical regions have reported ineffectiveness of PCV13 against serotype 3 [14, 35-38], although a few have reported decrease in serotype 3 following PCV13 implementation [39, 40]. We show a nearly significant increase in serotype 3 following PCV13 implementation in EJ (p=0.056) and no change after PCV10 implementation in PA.…”

Section: Discussionmentioning

confidence: 50%

Comparison of early effects of PCV7, PCV10 and PCV13 on S. pneumoniae (SP) nasopharyngeal carriage in a population based study; the Palestinian-Israeli Collaborative Research (PICR)

Seir¹,

Azmi

Hamdan³

et al. 2018

Preprint

View full text Add to dashboard Cite

BackgroundPneumococcal conjugate vaccines (PCVs), PCV10 and PCV13, are currently used in different countries. We have previously reported the effectiveness of PCV7, following its introduction in Israel and before PCVs were introduced in Palestine. Here, we extended the study and compared the initial impact of PCV10 to that of PCV7/13.MethodsFour cross-sectional surveys of S. pneumoniae carriage among children <5y through 2009-2014 were preformed among two proximate populations, living under two distinct health authorities, with different vaccination policies. In East-Jerusalem (EJ), PCV7 was implemented in 2009 and replaced by PCV13 in late 2010, while in Palestine (PA), PCV10 was implemented in 2011.ResultsA total of 1267 and 2414 children from EJ and PA were screened. Implementation of both PCV7 (in EJ) and PCV10 (in PA) did not affect overall S. pneumoniae carriage (∼30%), but resulted in a significant decrease in carriage of VT7 strains. In the pre-vaccine era, VT7/VT13 strains consisted 47.0%/62.0% and 41.2%/54.8% of pneumococci in EJ and PA, respectively. A 48.6% and 53.9% decrease was observed within 3 years of PCV7 implementation in EJ (p= 0.001) and PCV10 in PA (p<0.0001), respectively. These vaccination policies also resulted in ∼50% reduction in VT13-added serotypes especially 6A (from 11.0% to 0.0% (EJ) and 9.5% to 4.9% (PA)). Three years after PCV13 implementation in EJ, an additional 67% decrease in VT13 strains was observed, yet an increase in serotype 3 was observed (0.0% to 3.4%, p=0.056). The prevalence of non-VT13 strains increased during the study period from 38% and 45.3% to 89.8% and 70.7%, in EJ and in PA respectively.ConclusionsWithin the first three years following PCV implementation, we observed similar reductions in carriage of VT10 and VT13 strains with either vaccination policies, with no effect on overall carriage. Further follow-up is needed to compare the long-term effects.

show abstract

“…[21] Several key points should be made:

Pneumococcal phase variation in the NP converts high capsule-expressing pneumococci (opaque phenotype) into less capsule-expressing pneumococci (transparent phenotype) and this process facilitates the establishment of commensal carriage. [16]

Most anti-polysaccharide capsule antibodies, which are naturally acquired by colonization or induced by PCVs, easily access their abundant target polysaccharide antigens resulting in a decreased incidence of vaccine serotype NP colonization (an exception is the lack or variable reduction of IPD caused by serotype 3 observed in Denmark, UK and USA [17,22,23]), and thereby, reduced rate of infection. [24 ] However, naturally acquired protection against IPD depends on antibody to protein antigens rather than capsule as shown in a murine model using human antibodies.…”

Section: Capsular Polysaccharide Versus Protein-directed Antibody Effmentioning

confidence: 99%

“…Most anti-polysaccharide capsule antibodies, which are naturally acquired by colonization or induced by PCVs, easily access their abundant target polysaccharide antigens resulting in a decreased incidence of vaccine serotype NP colonization (an exception is the lack or variable reduction of IPD caused by serotype 3 observed in Denmark, UK and USA [17,22,23]), and thereby, reduced rate of infection. [24 ] However, naturally acquired protection against IPD depends on antibody to protein antigens rather than capsule as shown in a murine model using human antibodies.…”

Section: Capsular Polysaccharide Versus Protein-directed Antibody Effmentioning

confidence: 99%

Pneumococcal whole-cell and protein-based vaccines: changing the paradigm

Pichichero

2017

Expert Review of Vaccines

View full text Add to dashboard Cite

Introduction. Epidemiologic evaluations of Streptococcus pneumoniae nasopharyngeal (NP) colonization and pneumococcal disease suggest that newer serotypes in future formulations of pneumococcal conjugate vaccines (PCVs) are needed and there may need to be continued reformulations because there are many new emerging serotypes expressed by pneumococci. Areas Covered: Mechanisms of protection by next-generation whole-cell vaccine (WCV) and/or multi-component pneumococcal purified protein vaccines (PPVs) in development for prevention of pneumococcal infections. Expert Commentary: A long-term strategy for prevention of pneumococcal disease will likely include WCV and PPVs. However these vaccines will impact disease pathogenesis in a different manner than PCVs. Prevention of pneumococcal NP colonization should not be expected, nor is it desirable because risks for NP colonization by other replacement organisms into the ecological niche vacated by all pneumococci may have consequences. The expression biology of capsule and surface protein antigens are phase dependent. Therefore, the immune response will be different and the mechanism of protection divergent. WCVs and PPVs may be alternative strategies in low income developing countries to protect against invasive disease and reduce NP carriage load.

show abstract

The incidence of invasive pneumococcal serotype 3 disease in the Danish population is not reduced by PCV-13 vaccination

Cited by 45 publications

References 12 publications

Complicated pneumococcal pneumonia with pleural effusion or empyema in the 13‐valent pneumococcal conjugate vaccine era

Complicated pneumococcal pneumonia with pleural effusion or empyema in the 13‐valent pneumococcal conjugate vaccine era

Comparison of early effects of PCV7, PCV10 and PCV13 on S. pneumoniae (SP) nasopharyngeal carriage in a population based study; the Palestinian-Israeli Collaborative Research (PICR)

Pneumococcal whole-cell and protein-based vaccines: changing the paradigm

Contact Info

Product

Resources

About